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“The best designers in the world all squint when they look at something. They squint to see 
the forest from the trees — to find the right balance. Squint at the world. You will see more, 
by seeing less”. 
 
John Maeda 
Associate Director of Research, Media Arts and Sciences, 
Massachusetts Institute of Technology 
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OMISSIS 
Dott. ssa Valentina Ambrosini 
Curriculum Seguito Indirizzo Internistico – Malattie dell’Apparato Respiratorio 
 
Titolo tesi di Dottorato "PRE-CLINICAL IMAGING: SMALL ANIMAL PET AND 
CT APPLICATIONS IN PNEUMOLOGY, ONCOLOGY AND CARDIOLOGY". 
 
Presentazione  La Dott.ssa Ambrosini ha prevalentemente sviluppato studi sulle 
applicazioni cliniche e pre-cliniche della PET in oncologia, pneumologia e cardiologia. 
L’attività di ricerca pre-clinica è stata focalizzata allo studio, mediante PET per piccoli 
animali, di modelli murini di neoplasia umana (carcinoma del polmone e linfoma) e di 
modelli di infarto miocardico indotto chirurgicamente in ratti. 
L’attività di ricerca, clinica e pre-clinica, è stato eseguita presso il Dipartimento di 
Scienze Radiologiche ed Istocitopatologiche dell’Universita’ di Bologna, sotto la 
supervisione del Prof Mario Fabbri, svolgendo attività presso il Laboratorio di Imaging 
Pre-clinico ed il Centro PET della UO di Medicina Nucleare del Policlinico S.Orsola-
Malpighi, Bologna. 
I risultati preliminari suggeriscono che la PET è una tecnica molto utile per selezionare gli 
animali in cui la neoplasia ha attecchito, per monitorare la crescita tumorale nel tempo, 
fornendo utili indicazioni sull’attività metabolica delle lesioni. La PET per piccoli animali è 
inoltre untile per la valutazione dell’estensione dell’area infartuale indotta chirurgicamente 
nell’animale e può essere utilizzata per valutare il recupero funzionale del miocardio dopo 
terapie rigenerative sperimentali 
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SECTION 1 
INTRODUCTION TO PRE-CLINCAL IMAGING 
 
Pre-clinical imaging may be defined as ‘the visual representation, characterization, and 
quantification of biological processes at the cellular and sub-cellular levels within intact living 
organisms. It is a novel multidisciplinary field, in which the images produced reflect cellular 
and molecular pathways and in-vivo mechanisms of disease present within the context of 
physiologically authentic environments’ [1]. 
Conventional imaging technologies rely mostly on non-specific morphologic changes to 
differentiate pathologic from normal tissues rather than identifying specific molecular events 
responsible for the presence of disease. On the contrary, molecular imaging exploits specific 
molecular probes as the source of image contrast. Imaging is a novel approach to early detect 
the presence of disease (e.g. early diagnosis of tumour) and to monitor the metabolic changes 
over time. Moreover, novel strategies , such as the reporter-gene/reporter-probe, allow the in-
vivo detection of gene-expression.  
The advent of molecular imaging strategies follows the recent advances in molecular and cell 
biology techniques, the use of transgenic animal models, the availability of newer imaging 
drugs and probes that are highly specific, and the development of high resolution small-
animal imaging instrumentation. 
Molecular imaging in living subjects offers distinct advantages when compared with 
conventional in vitro and cell culture research and it can be considered as a bridge between in-
vitro studies and clinical practice. The main advantages of molecular imaging  can be 
summarized as follows: it eliminates the need to kill mice as part of their phenotype 
determination; by serial imaging of the same animal over time, it is possible to acquire 
functional data of disease progression and allows to identify mutants that are otherwise 
difficult to interpret with data taken at a single time point; it allows concomitant visual and 
analytical biological phenotyping of animals; and it offers the researcher the opportunity to 
study the disease using multiple imaging strategies (e.g., by using different imaging reporter 
probes or modalities). Basically all imaging modalities used in humans can be employed in 
rodent models (PET, CT, MRI, US, optical imaging, SPECT) of disease (Figure 1.1).  
Small animal PET (Positron emission tomography) and CT (computed tomography) are the 
imaging modalities used in the protocols described in this thesis work.  
The first author to suggest small animal PET as a ‘sensitive and informative tool to study 
biological processes’ was Michael Phelps in 2000 [2]. Small animal PET offers several 
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advantages for animal studies. It is a whole-body, functional, non-invasive technique that 
allows repetitive imaging of the same animal over time, therefore reducing the total number of 
animals used for each experiment and offering the advantage of closely following the 
metabolic changes  of the disease under study in the same animal at different time-points. For 
this reason, small animal PET is a promising tool to assess the response to novel drugs and to 
evaluate the bio-distribution of novel PET tracers. Another relevant advantage of small animal 
PET is the very high spatial resolution (approximately 1,2-1,6mm). Recently it was also used 
to in-vivo assess gene expression using the reporter-gene/reporter probe approach. 
Positron emission tomography records high-energy X-rays emitted from within the subject. 
Natural biological molecules can be labelled with a positron-emitting isotope that is capable 
of producing two X-rays through emission of a positron from its nucleus, which eventually 
annihilates with a nearby electron to produce two 511,000-eV X-rays at 180° apart. 
Positron-emitting isotopes frequently used include 15O, 13N, 11C, and 18F, the latter used as 
a substitute for hydrogen. Other less commonly used positron emitters include 14O, 64Cu, 
62Cu, 124I, 76Br, 82Rb, and 68Ga. Most of these isotopes are produced in a cyclotron [3], 
but some can be produced using a generator (e.g., 68Ga, 82Rb). Labelled molecular probes or 
tracers can be introduced into the subject intravenously and PET imaging can be performed in 
the anaesthetized animal. Data on the distribution and concentration of the radiotracer can be 
acquired. The most commonly used tracer in animal studies, as well as in humans, is 18F-
FDG, a glucose analogue labelled with 18F that is avidly taken up by highly proliferating 
cells (such as inflammatory cells or tumour cells) and is trapped inside the cell by 
phosporylation. Other radiotracers currently available include 11C-Choline, 11C-Mehtionine, 
68Ga-DOTANOC and 18F-DOPA. 
The sensitivity of PET is relatively high in the range of 10−11–10−12 mole/L, and is 
independent of the location depth of the reporter probe of interest. Typically, several million 
cells accumulating reporter probe have to be in relative close proximity for a PET scanner to 
record them as a distinct entity relative to the background [1].  
The accuracy of small animal PET functional data can be increased using an anatomic 
imaging modality that allows a better localization of high radiotracer uptake areas. Images in 
computed tomography are obtained when component tissues differentially absorb X-rays as 
they pass through the body [4]. A low-energy X-ray source of 30–50 kVp (of considerably 
lower energy than in clinical CT scanners) and a detector rotate around the animal, acquiring 
volumetric data. Most mouse CT images are collected with high-resolution phosphor 
screen/CCD detectors to optimize image quality. A scan of an entire mouse at 100-µm 
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resolution takes 15 min. Higher-resolution (50-µm) images are achievable with longer 
scanning times (that however imply a higher dose delivered). The system spatial resolution is 
primarily limited by the pixel sampling rate, the X-ray source size, and blurring in the 
phosphor screen. A limit of performing CT in living animals is the radiation dose (0.6 Gy per 
scan; 5% of the LD50 for mice), that can limit serial imaging of the same animal over time. 
Unlike MRI, CT has relatively poor soft tissue contrast, often making it necessary to 
administer iodinated contrast media to delineate organs or tumours. Dedicated high-resolution 
small animal CT scanners are currently available for anatomical imaging of animal models of 
disease [5,6,7], thus complementing the functional information obtained by other modalities.  
 
Aim of this thesis work was to assess the usefulness of small animal PET and CT in the 
assessment of different rodent models of human disease (squamous cells lung carcinoma, 
anaplastic large cells lymphoma and ischemic heart disease). 
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FIGURES SECTION 1 
 
Figure 1.1 Multiple imaging modalities are available for small-animal molecular imaging. 
(A) microPET, (B) microCT, (C) microSPECT, (D) Optical reflectance fluorescence, (E) 
microMRI, (F) Optical bioluminescence. 
Massoud TF, Gambhir SS. Genes Dev. 2003 Mar 1;17(5):545-80. 
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SECTION 2 
SMALL ANIMAL PET and CT APPLICATIONS IN PNEUMOLOGY (murine model of 
lung squamous cells carcinoma) 
 
 
ABSTRACT 
Background: small animal imaging has become a relevant research field in pre-clinical 
oncology. In particular, metabolic information provided by small animal PET are very useful 
to closely monitor tumour growth and assess therapy response in murine models of human 
disease. Although there are various murine models for human lung adenocarcinomas, models 
for squamous cells lung carcinoma, the most frequent form of human cancer, are few. 
Aim: to assess the feasibility of 18F-FDG small animal PET to monitor tumour growth in a 
chemically induced model of lung squamous cells carcinoma. 
Materials and Methods: 19 NIH Swiss mice were skin painted by NTCU (N-nitroso-tris-
chloroethylurea) twice a week with a three day interval for 8 months and 10 NIH Swiss mice 
skin painted with NTCU-solvent (acetone) were used as controls. 18F-FDG PET was 
performed under sevofluorane anaesthesia and oxigen supplementation at 2,4,6 and 8 months 
from initial treatment. Images were assessed by visual analysis and semiquantitatively: 
considering the diffuse distribution of tumour development, the mean of the counts/pixel 
measured at three lung levels (TLA), corrected for the effective dose injected and for decay, 
was used for comparison between cases and controls. Pathological evaluation was carried out 
from the time of the first positive PET results in a subgroup of the whole population to assess 
correlation with PET findings. Small animal CT was performed at 8 months in an animal 
subgroup. 
Results: In both terms of visual analysis and measure of total lung activity, 18F-FDG PET at 
2 and 4 months from initial treatment were comparable in cases and controls. At 6 months, 
PET images showed a faint and diffuse uptake over both lung fields with multiple focal areas 
of increase tracer uptake that merged into confluent masses at 8 month, seriously subverting 
lung architecture. Total lung activity was significantly higher in cases vs controls at 6 (p= 
0,00000668) and 8 months (p=0,00000043) from initial treatment and paralleled the 
progressive lung involvement and histological severity. 
Conclusions: 18F-FDG PET may be useful in the assessment of this chemically induced 
murine model of lung squamous cells carcinoma. The TLA may be used as a measure of 
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tumour metabolic activity of the tumour-bearing animals and may be useful in new drug 
testing studies. 
 
INTRODUCTION 
Lung cancer is the most common cause of death for cancer in both man and women in 
developed countries [1]. The role of 18F-FDG PET in the assessment of lung cancer is well 
established in humans for the characterization of lung lesions, diagnosis, initial staging, early 
assessment of tumour response to therapy and early identification of disease relapse [2,3,4,5]. 
Moreover, PET is a novel technology for molecular imaging essays of gene expression, signal 
transduction and evaluation of the outcomes of processes being modified in the mouse or in 
the patient, that offers the advantage of providing in vivo biological characterization of the 
disease  [6]. The recent development of small animal PET scanners represents a new and non 
invasive approach to study rodent model of human disease, providing a novel tool to closely 
follow tumour growth over time, to test new anticancer drugs and to study the biological 
processes at the basis of tumour transformation [7]. 
Mouse models of tumourigenesis of many human tumours are currently available and are 
widely used in both basic research and therapeutic trials [8,9,10]. The best murine models of 
human disease are able to accurately reproduce aspects (angiogenesis, tumour-stromal 
interaction, hormone dependency) of human cancer development and molecular mechanisms 
at the basis of tumourigenesis, tumour progression and metastasis, thus representing a useful 
tool to study human carcinogenesis [8,10].  
Murine lung tumours present many similarities with the human counterparts [9] and different 
murine models of lung carcinogenesis are currently available [11,12,13]. The most commonly 
used xenograft models [14-20] obtained by subcutaneous or intratracheal injection of human 
derived tumour cell lines require an immunocompromised host and lack their original 
microenviroment, including tumour derived stroma that has been recently shown to play a 
role in tumour development and progression. Although there are well established transgenic 
models of adenoma and adenocarcinoma [21,22], there is no well established model of 
squamous cells carcinoma [11]. Since squamous cells carcinoma is by far the most frequent 
form of lung cancer and drug efficacy may vary among different histotypes, it is crucial to 
identify a reproducible murine model of squamous cells carcinoma. The first report of 
squamous cell carcinoma induced in non-immunocompromised mice by NTCU (N-nitroso-
tris-chloroethylurea) is by Lijinsky et al in 1988 [23]. The same experiment was later repeated 
by Wang et al [11] who reported how different mouse strains presented variable tumour 
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susceptibility to NTCU and the NIH Swiss strain presented the highest tumour susceptibility. 
Moreover, they demonstrated that NTCU-induced tumours presented many similarities with 
the histopathological features of human squamous cells carcinoma.  
 The aim of the present study was to assess non small cells lung cancer (NSCLC) 
development in a chemically-induced (using N-nitroso-tris-chloroethylurea, NTCU) mouse 
model of squamous cells carcinoma of the lung by small animal PET. 
 
MATERIALS AND METHODS 
To induce NSCLC development, nineteen 7 weeks old, female NIH Swiss mice were skin 
painted with a known mutagen (N-nitroso-tris-chloroethylurea, NTCU), according to the 
protocol proposed by Wang [11]. Forty-eight hours after dorsal shaving, each animal was skin 
painted with a drop of NTCU (0.04M, 25ul) twice a week, with a 3-day interval for 8 months. 
Ten 7 weeks old, female NIH Swiss mice, were used as controls and were skin painted with 
the same amount of NTCU solvent (Acetone). 
Animals were handled and closely monitored for their health at the  IOR-Istituti Ortopedici 
Rizzoli, Bologna. All experiments were approved by the Ethical Committee of the University 
of Bologna. 
PET scans were carried out under sevofluorane (5%) anaesthesia (VetEquip Complete 
Anaethesia System, Pleasanton, CA) and oxigen supplementation (1L/min). Each anesthetised 
animal was injected with 20 MBq of 18F-FDG in the tail vein (injected volume <0,15ml) and 
subsequently allowed to wake up during the uptake time (60minutes). The residual dose in the 
siringue was measured to verify the effective dose injected. At the end of the uptake time, 
PET image acquisition was performed with a small animal PET tomograph (GE eXplore 
Vista DR) in the anesthetised mouse placed prone on the scanner bed (2 bed positions, 
15minutes/each bed position). Once the scan was completed the animal was allowed to wake 
up in a warmed recovery box. 
18F-FDG PET was performed at 2, 4, 6 and 8 months from the initial treatment with either 
NTCU or Acetone. FDG-PET images were reconstructed iteratively (OSEM 2D) and read in 
three planes (axial, sagittal and coronal). The scan was considered positive if any area of 
increased non-physiologic FDG uptake was observed. 
CT scans were carried out using a small animal CT tomograph (GE eXplore Locus) in two 
cases and in two controls, at 8 months from initial skin painting ( ). 18F-FDG filled 
microspheres were fixed with adhesive tape on the animal body and used as reference marks 
to accurately fuse CT and PET separately acquired images.  
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Pathology sections were obtained from the time of the first positive PET scan in a subgroup of 
the whole sample. Three cases were sacrified after the third PET and six animals (four cases 
and 2 controls) were sacrified after the fourth PET scan and autopsy was carried out.  
 
Data analysis 
Continous variables were expressed as mean±standard deviation. Differences among groups 
were considered significant when p<0,005.  
Considering the disease diffuse distribution over the lung fields, for PET image analysis the 
lungs were considered at three axial levels: lung apex, mid-lung and lung bases. For each 
level, mean counts/pixel were recorded in a region of interest including all lung fields. Total 
lung activity (TLA) was calculated for each animal as the mean of the three levels. TLA was 
normalized for the injected dose (TLAI) in each case and corrected for decay (TLAI = 
TLA/(injected dose- residual dose).  
For each PET scan, mean TLAI was calculated for cases and controls and data were compared 
using the T-test for unpaired data.   
 
RESULTS 
In our study a chemically induced murine model of squamous cells carcinoma was used to in-
vivo monitor tumour development over time by small animal PET at 2,4,6, and 8 months from 
initial treatment. Overall, PET scan was performed in 19 cases and 10 controls at 2 and 4 
months from initial treatment, in 15 cases and 9 controls at 6 months, in 5 cases and 9 controls 
at 8 months.  
In our series we observed some mortality after four months from initial treatment (4 cases and 
1 control were found dead in their cages between four and six months; 6 cases were found 
dead at 7 months) and case mice presented a significant (p<0,0002) lower weight then 
controls (Figure 2.1). It was not possible to perform autopsy in any of these animals. 
Pathological studies were performed starting from the time of the first PET positive result. 
Three animals were sacrified after the third PET scan and four animals and two controls after 
the fourth PET acquisition.  
At 2 and 4 months from initial treatment, both case and control mice showed similar findings 
at 18F-FDG PET. Starting from the third scan (6months), it was possible to detect the 
presence of a diffuse lung disease with a faint background FDG uptake with multiple areas of 
increased tracer uptake in NTCU-treated mice. FDG-positive areas merged into confluent 
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areas of pathological uptake involving all lung fields in the images acquired at 8 months from 
initial treatment (Figure 2.2).  
To quantify the activity in the whole lung, the mean of the activity measured at three lung 
levels (TLAI) was used for comparison between cases and controls. There were no differences 
in FDG uptake in the two groups in the earliest scans while in the latest PET acquisitions the 
tracer uptake was significantly higher in mice treated with NTCU (Figure 2.3). In particular, 
mice skin-painted with NTCU showed the highest values (PET at 6 months: TLAIcases=39.5 vs 
TLAIcontrols=20.3, p= 0,00000668; PET at 8 months: TLAIcases= 48.8 vs 25.6, p=0,00000043).  
Mean TLAI increase in case mice over time reflects the progressive changes observed in the 
histological sections obtained from the first PET positivity in a subgroup of the whole sample.  
Overall, histological evaluation was carried out in nine animals (3 cases after the third PET 
scan, 4 cases and 2 controls after the fourth PET scan). Pathologic evaluation of the lungs of 
the three cases sacrified at 6 months, when TLAI was double the one observed in controls, 
demonstrated the presence of diffuse inflammation involving all lung fields with lymphocytes 
inflammatory exudate filling the alveoli, foci of bronchial epithelial hyperplasia and 
metaplasia and multiple nests of squamous cells carcinoma with a prominent central 
distribution (Figure 2.4A-B). Among the animals sacrified after the fourth scan, control 
animals had normal lung fields and intact lung architecture (Figure 2.4C) while in the NTCU-
treated mice lung architecture was completely subverted, with squamous tumour cells 
infiltrating the air spaces and franc bronchiolar epithelium metaplasia and displasia (Figure 
2.4D-E). Squamous cells carcinoma areas appeared as non-capsulated masses, with stratified 
squamous cells with hyperchromatic nuclei, irregularly shaped and forming  sheet or nests of 
tumour cells all over the lungs. 
Comparing the trend of TLA over time in the animals in which 4 PET scans were performed 
and histological evaluation after 8 months from initial treatment was available, mean TLAIcases 
was significantly higher then TLAIcontrols starting from the third acquisition.  
Small animal CT performed at the end of the fourth PET scan in two cases showed the 
presence of increased attenuation involving all lung fields and with solid confluent nodules 
corresponding on fused images at the areas of increased FDG uptake. 
 
DISCUSSION 
PET is widely used in human oncology and its role in the assessment of lung tumour bearing 
patients is well documented. Since lung caner is still the leading cause of tumour death in 
western countries, it is crucial to identify animal models that accurately reproduce the features 
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of the human disease, in order to have a valid tool to study both the mechanisms at the basis 
of carcinogenesis and to test potentially therapeutic new drugs.  
Recent advances in in-vivo animal imaging offer many advantages for studying animal 
models of human disease over conventional in vitro studies [24,25,26]. In particular, small 
animal PET is an in-vivo whole body, non-invasive technique that allows repetitive imaging 
of the same animal over time, providing information on the metabolic activity of the 
pathologic areas, allowing to closely monitor tumour growth and avoiding the need to 
sacrifice the animal at fixed time intervals [7,24]. Moreover, animal PET studies have a high 
spatial resolution and allow both a visual analysis of  the pathologic areas and a numerical 
measure of the biological phenomena under study [27]. This is particularly helpful in drugs 
efficacy studies, where the reduction in lesion size alone is an inaccurate measure of drug 
response, while the possibility to compare the lesions metabolic activity before and after the 
drug administration directly reflects the changes in the tumour viable cell fraction. 
Murine models of lung squamous cells carcinoma were reported to accurately reproduce the 
human tumour features. The induction of squamous cells carcinoma by NTCU was first 
described in 1988 [23] and the experiment was recently repeated in different strains of mice to 
test their susceptibility to tumour development [11].  
In this paper, we repeatedly studied a group of 19 NTCU-treated mice by 18F-FDG small 
animal PET (every 2 months , up to 8  months) and used 10 mice treated with NTCU solvent 
as controls.  
Our data show that although the results of the first two PET acquisitions were comparable in 
cases and controls in terms of both visual analysis and measure of lung activity, significant 
changes were observed starting from the third PET acquisition, when pathology sections 
revealed the presence of sparse nests of squamous cancer cells, bronchial metaplasia and 
alveoli-filling inflammatory exudate in NTCU-treated mice. At 6 months NTCU-treated mice 
presented multiple areas of increased FDG uptake on a diffusely faint uptake background 
while in the images acquired at 8 months FDG-positive areas merged into masses that 
involved almost all lung fields. To semiquantify the total activity present in the tumour-
bearing lungs, we used a metabolic parameter (TLA) derived from the mean activity at three 
lung levels.  The TLA increased over time only in case mice starting from the third PET 
acquisition and further increased at the fourth PET scan, while remained always low in 
controls. Although this murine model has been well documented from an histological point of 
view (http://emice.nci.nih.gov), pathological studies were performed starting from the time of 
 16 
the first PET positive result to assess if TLA could be used to non-invasively monitor tumour 
bearing animals.  
At the time of the first PET positive result, when pathology confirmed the presence of 
multiple areas of tumour cells arranged in either nests or with a lobular distribution that 
effaced the normal pulmonary architecture, NTCU-treated mice presented a TLA double the 
one observed in controls. TLA further increased at 8 months, when PET images showed an 
even more diffused disease and pathology revealed large areas of neoplastic cells with almost 
no spared lung parenchyma. 
TLA correlated well with disease presence and with the progressive changes observed on 
histological sections, revealing the presence of disease from 6 months from initial treatment 
and an increased tumour burden and a more aggressive disease in the latest scans.  
Ideally, the effect of new anticancer drugs should be assessed on the early phases of tumour 
development, to ensure the presence of small well-vascolarized nodules with highly 
proliferating cells and with no necrotic areas. Small animal PET may be used in new drugs 
testing studies to identify tumour-bearing animals in early phases of cancer development, and 
our data show that in this murine model changes in TLA closely reflect the progressive 
changes from multiple areas of tumour cells and metaplasia to widespread tumour. Since we 
observed an increase in TLA with increasing tumour burden, the measure of TLA might be 
useful in studies assessing the efficacy of new anticancer drugs in this murine model.  
Small animal CT performed at 8 months after the fourth PET confirmed the diffuse pattern of 
disease distribution and showed that increased attenuation areas identified by CT 
corresponded to increased FDG uptake areas in PET images. 
It is to be noted that although the NIH Swiss mice were reported to be the most resistant to 
NTCU-induced toxicity among eight different mouse strains [11], we observed some 
mortality starting from four months after initial treatment, with our initial population reducing 
of 40% at the end of the experiment. Unfortunately we could not perform autopsy in the mice 
that we found dead in their cages. Since there were no signs of any infectious disease in the 
other mice kept in the same cages of the ones who died, we can speculate their deaths were 
only related to NTCU-induced toxicity. It would be interesting to know if lower NTCU-doses 
for a shorter period of time would invariably lead to tumour formation and to lower toxicity 
and in this contest small animal PET studies may be useful in the early assessment of tumour 
development. 
In preclinical studies it is crucial to identify the most suitable animal model for the disease or 
the biological process under study. The present murine model of human squamous cells 
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carcinoma offers the advantage of accurately reproducing the features of the human tumour, 
recapitulating all the steps from epithelial hyperplasia to carcinoma and our data show that it 
is possible to closely monitor disease progression by measuring total lung activity in serial 
PET scanning. In particular, 18F-FDG small Animal PET can identify tumour formation as 
early as 6 months from initial treatment.  Nevertheless the high mortality we experienced may 
rise the question of weather it would be possible to induce tumour formation with lower 
NTCU doses to reduce toxicity. 
 
FUTURE DIRECTIONS.. 
Although this model is quite accurate in  reproducing the pathological steps of human tumour 
development, it takes a long time to induce tumour formation and the diffuse nature of lung 
involvement renders semi-quantitative analyses of tumour activity more difficult (ideal 
condition would be a high uptake area over a cold background), therefore in the next future 
murine xenograft models of human lung cancer will be studied by small animal PET in order 
to assess if they can represent more suitable models for tumour assessment and for drug 
testing studies. 
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FIGURES SECTION 2  
 
Figure 2.1. Variations of body weight in case and controls mice over time. NTCU-treated 
mice presented a significant weight loss compared with controls.  
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Figure 2.2. 18F-FDG small animal PET and CT axial images of a NTCU-treated mouse at 8 
months from initial treatment. 18F-FDG PET showed a diffuse faint background uptake all 
over the lung fields with multiple areas of focal increased tracer uptake. Positive PET areas 
corresponded to increased attenuation on CT.  
 
 
 
p=0.0002 
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Figure 2.3. Mean TLA variations over time in case and controls mice. Case mice presented a 
significant TLA increase at the third PET (p=0,00000668) and further more at the fourth PET 
(p=0,00000043) scan. 
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Figure 2.4.  
 
Histological sections of case and control mice. NTCU-treated mouse at 6 months (A, 20x) 
from initial treatment shows bronchial hyperplasia, inflammatory exudates filling the alveoli 
and focal areas of squamous cells carcinoma (B, 10x). Normal lung architecture in a control 
mouse at 8 months (C, 10x). NTCU-treated mouse at 8 months from initial treatment shows a 
multiple nests of tumour cells infiltrating all lung fields (D, 10x; E, 20x). 
A 
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SECTION 3 
SMALL ANIMAL PET APPLICATIONS IN ONCOLOGY (murine xenograft model of 
anaplastic large cells human lymphoma) 
 
 
ABSTRACT 
Purpose: to assess if small animal PET is useful to serially monitor the development of a 
human anaplastic large cells lymphoma (ALCL) murine xenograft and to early select tumour 
bearing animals. 
Methods: Human ALCL Karpas 299 cell line was subcutaneously injected in 6 weeks-old 
NOD/SCID mice (107cells/mice in 150 uL FBS) at right flank level. Small animal 18F-FDG 
PET was serially performed (i.v. injected dose: 20MBq in <0.15ml, uptake time: 60 minutes, 
image acquisition: 1 bed position of 15 minutes): early PET at 2 days after cells inoculation in 
4/8 mice and at 4 days in 4/8; later PET scans were performed in all animals at 7, 14, 21, 28 
days after inoculation. Images were evaluated visually and the tumour to background ratio 
(TBR) was used for semi-quantitative analysis. Pathology sections were obtained in all cases. 
Results: PET detected the presence of the tumour as early as seven days after inoculation in 
4/8 mice and at 14 days in 2/8. Of the two remaining mice, one died after the first PET scan 
(thus preventing any evaluation of detection time) while the other showed a microscopic 
neoplastic infiltration at tracheal level at autopsy.  
Mean TBR progressively increased in all positive cases, particularly in the first 3 weeks, 
reaching a plateau afterwards. 
Conclusions: PET was positive in 6/8 (75%) animals, detecting the presence of viable tumour 
cells earlier than macroscopic evaluation, thus may be used to early identify tumour bearing 
animals. 
 
 
 23 
INTRODUCTION 
Primary systemic anaplastic large cells lymphoma (ALCL) accounts for about 5% of all non-
Hodgkin lymphomas in adults and 20-30% of large-cell lymphomas in children [1]. ALCL 
represents a heterogeneous group of aggressive non-Hodgkin lymphomas characterized by 
strong expression of CD30 and frequent t(2;5) chromosome translocation [2]. 
Notwithstanding its responsiveness to chemotherapy, about 30-40% of the patients die after 
intensive treatment and standard therapy is associated with considerable toxicity, particularly 
bothersome in the paediatric population. Therefore alternative new drugs need to be 
developed not only for relapsing patients but also as first line treatment. 
18F-FDG PET is widely used for the assessment of lymphoma in human patients for either 
staging, assessment of the response to therapy and early detection of relapse, influencing in 
many cases the patients clinical management [3-11].  
Presenting many similarities with human disease, murine models of lymphoma are useful 
tools for pre-clinical studies. In recent years molecular imaging procedures (PET, CT, optical 
imaging, MRI)  have been more and more employed in oncological preclinical studies [12-
21]. Among the different imaging techniques, small animal PET shows a good spatial 
resolution (1.0-1.5 mm) [22] and is the only method allowing sequential evaluation of the 
same animal over time. Therefore small animal PET is particularly useful for monitoring the 
metabolic features of a lesion, representing a valid tool to assess the response to treatment 
[23]. The ability to early detect the presence of active disease, hopefully before macroscopic 
evaluation, is particularly relevant for new drugs testing studies since ideally the effect of 
potentially therapeutic molecules is better assessed in small, well vascularized masses without 
necrosis. Therefore it is crucial to identify a suitable murine model of disease that can be 
accurately monitored by PET imaging. 
Xenograft models present some limitations mainly related to the formation of a chimeric 
neoplastic tumour, to the need of an immunocompromised host and, in some cases, to the 
heterotopic site of tumour formation; nevertheless xenografts models have been widely 
employed, especially for drug testing studies, for their low cost and reproducibility. On the 
other hand, transgenic models are orthotopic but are characterized by an entirely murine 
tumour mass and are very expensive. 
Karpas 299 xenograft murine model, expressing the NPM-ALK fusion gene, has been used in 
different studies investigating the role of novel molecules for lymphoma therapy [24-26]. To 
our knowledge there are no reports evaluating the imaging features of this lymphoma murine 
model and the metabolic changes of the tumour mass over time. 
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Aim of the present study was to assess if a xenograft model with a well established human 
ALCL cell line could be accurately monitored by small animal PET over time and if PET 
could be used to early assess the presence of the tumour and therefore proposed to select mice 
bearing tumours early in the course of  the disease to promptly start the testing of a new drug.  
 
MATERIALS AND METHODS 
Cell  culture 
Human Anaplastic Large Cell Lymphoma Karpass 299 cell line (established from a 25 years 
old ALCL patient) was purchased from DSMZ (Germany) [1,27]. Cells were maintained in 
90% RPMI medium 1640 supplemented with 10% FBS at 1.0-2.0 x 106 cells/ml (maximal 
density of about 2-3 x 106 cells/ml). Cells cultures were kept at 37 °C with 5% CO2.  
Karpas 299 immunological profile, as provided by DMSZ, includes: CD2 -, CD3 -, CD4 +, 
CD5 +, CD6 -, CD7 -, CD8 -, CD10 -, CD13 +, CD14 -, CD15 -, CD19 -, CD20 +, CD25 +, 
CD30 +, CD33 -, CD34 -, CD71 +, HLA-DR +, TCRalpha/beta -, TCRgamma/delta -. 
Cytogenetic analysis shows human hypodiploid karyotype with 14% polyploidy - 44(42-
45)<2n>XY, -10, -22, t(1;17)(q22;p11), t(2;5)(p23;q35), del(6)(q23), der(13)t(13;?)(p12;?), 
der(14)t(14;22)(p12;q11), der(19)t(19;?)(q13;?), del(22)(q12) - expression of NPM-ALK 
fusion gene was detected by RT-PCR analysis. 
 
Animal model 
Eight six weeks-old severely immunocompromised NOD/SCID mice were used in the study. 
Animals were purchased from Charles Rivers Laboratories (Italy). Mice mean weight was 
25.9gr (range 22-30gr). Animals were given food and drink ad libitum, manipulated under 
sterile conditions and closely monitored for their health at the Experimental Surgery 
Laboratory, Istituti Ortopedici Rizzoli. Karpas 299 cells growing exponentially were 
resuspended in PBS and inoculated into mice subcutaneously (1x107 cells/mouse in 150 uL 
FBS) at right flank level. 
The whole experiment was approved by the Ethical Committee of the University of Bologna. 
 
Tumour Imaging by FDG Small Animal PET 
PET scans were carried out under sevofluorane (5%) anaesthesia (VetEquip Complete 
Anaethesia System, Pleasanton, CA) and oxigen supplementation (1L/min). Each 
anaesthetised animal was injected with 20 MBq of 18F-FDG in the tail vein (injected volume 
<0.15ml) and subsequently allowed to wake up during the uptake time (60minutes). The 
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residual dose in the syringe was measured to verify the effective dose injected. At the end of 
the uptake time, PET image acquisition was performed with a Small Animal PET tomograph 
(GE eXplore Vista DR) in the anesthetised mouse placed prone on the scanner bed. Total 
acquisition time was 15 minutes. Since the axial field of view was 4 cm, a single bed position 
was sufficient to cover the whole body. Once the scan was completed, the animal was allowed 
to wake up in a warmed recovery box.   
Early PET imaging was obtained at 2 days from cells inoculation in 4/8 animals and at 4 days 
in the remaining 4/8 animals. Later scans were performed in all animals at 7, 14, 21, 28 days 
from cells injection.  
FDG PET images were reconstructed iteratively (OSEM 2D) and read in three planes (axial, 
sagittal and coronal). The scan was considered positive if any area of increased non-
physiologic FDG uptake was observed. Cold areas located at the centre of a tumour mass 
were interpreted as areas of necrosis. Semi-quantitative analysis was carried out in all cases 
using the tumour to background ratio (TBR), placing the target region of interest (ROI) in the 
most active tumour area and the background ROI in the contra-lateral subcutaneous tissue 
(TBR=Max Count in the target ROI/ Mean count in the background ROI). 
 
Histology evaluation 
Pathological sections were obtained in all cases. Animals were sacrificed 30 days after tumour 
cells inoculation (6/8 cases). Autopsy was performed before the end of the study in the two 
animals that died during the experiment (one mouse died after the first PET and one animal 
died at 27 days from tumour cells injection). Pathology was used to confirm PET findings. In 
all cases the tumour was excised and samples from heart, lungs and peritoneum were obtained 
for histological evaluation. At macroscopic observation one mouse showed liver and kidney 
enlargement therefore liver and kidney samples were collected. In one case with all negative 
PET scans, samples were taken also from liver and intestine. 
Formalin fixed tissue samples were embedded in paraffin and 5µm sections were cut and 
stained with hematoxylin and eosin.  
 
RESULTS 
Early PET evaluation after tumour cells injection (in 4/8 animals at 2 days and in the 
remaining 4/8 mice at 4 days) was negative in all cases. Subsequently small animal PET 
identified the presence of lymphoma in 6/8 (75%) mice. A pathologic FDG uptake at 
inoculation site was evident at 7 days after implantation in 4/8 (50%) mice and at 14 days in 
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2/8 (25%) animals. Of the remaining two animals, one died after the first PET scan and 
autopsy did not reveal the presence of the tumour; PET scans carried out in the other mouse 
were negative at all time-points.  
In all cases PET detected the presence of viable tumour cells before macroscopic evaluation. 
Palpable tumours were observed at 14 days in 3/8 and at 21 days in 3/8 (overall mean 
17.5days),  therefore PET detected the tumour mass with an average of 8 days (range 7-14 
days) in advance.   
Serial PET documented a progressive increase in the metabolic activity of the tumour mass in 
all PET positive mice (Figure 1). In the latest scans, PET showed in 6/6 cases cold central 
lesion areas compatible with necrosis, secondary to tumour vascularisation incompetence. 
The lesions mean TBR presented a greater increase in the first three weeks, especially 
between 7 and 14 days, while in the latest scans the trend tends to a plateau, reflecting the 
necrotic changes in the tumour mass (Figure 2).  
Quite interestingly, in the two animals in which PET turned positive only at 14 days, the mean 
TBR at 14 days was higher (6.2) then the mean TBR observed in the animals that turned 
positive 7 days (4.4).  
Pathology sections of the tumour samples (Figure 3) showed in all cases the presence of an 
aggressive tumour, with pleomorphic lymphoma cells presenting a high mitotic and apoptotic 
rate. In all animals the lesions presented a big central necrotic area. The tumour often 
infiltrated adjacent tissues (muscles, abdomen wall, fat, peritoneal vessels) and organs, 
including kidneys (in one case), liver (in two cases), intestine (one case) and lung (in five 
cases). The involved lungs presented diffuse lymphoma cells infiltration with sparse foamy 
macrophages that filled the alveolar spaces without evident fibrosis. The widespread lung 
involvement prevented any considerations regarding the pulmonary TBR changes over time. 
Autopsy carried out in the single animal in which PET was negative at all time-points 
revealed the presence of a very small lymphoma infiltration embracing the trachea and 
esophagus with no macroscopically evident mass at neither tracheal nor at inoculation site.  
 
DISCUSSION 
Murine models of human cancer are valid tools to study tumour development over time and to 
test potentially curative new drugs. Xenograft models in particular are extensively used for 
new drugs testing for their low cost, reproducibility and similarities with human tumours. 
In recent years different imaging modalities, traditionally used for humans, such as PET, CT, 
MRI, optical imaging and SPECT have been designed for animal research. For new drugs 
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testing small animal PET offers many advantages over anatomical imaging modalities that 
rely only on size criteria for the evaluation of therapy response. PET offers the advantage of 
non-invasively providing functional information of the tumour lesion and is therefore very 
accurate for the assessment of the metabolic changes consequent to drug administration. 
Moreover, PET can detect the presence of viable tumour cells at a very early stage and this 
feature can be particularly helpful for identifying animals with very small, well vascularized 
tumours, an ideal setting for testing new drugs. However, before testing a new molecule, it is 
crucial to assess the metabolic characteristics of the tumour over time and the earliest time-
point when the lesion can be detected.  
Much attention has been directed to therapeutic drugs aimed at down-regulating NPM-ALK 
fusion protein expression or inhibiting the NPM-ALK signalling cascade [28,29] and recently 
siRNA were used to specifically down-regulate NPM-ALK fusion protein expression in 
Karpas 299 cell line in vitro inducing decreased cell proliferation and increased apoptosis 
[30]. 
Therefore, we chose a murine xenograft model using a well established ALCL cell line, 
carrying the t(2;5) chromosome translocation, in order to evaluate tumour development over 
time by small animal PET.  
In our sample, PET detected the presence of the tumour in almost all animals, identifying the 
earliest lesions at seven days after cells inoculation in the majority of cases; furthermore in all 
mice PET identified the tumour earlier then macroscopic evaluation (on average seven days in 
advance).  
In fact PET was positive in 6/8 mice, while in the remaining two cases there was no lesion 
that PET could have detected (one mouse died very early, the other did not develop a mass at 
inoculation site). 
These data are particularly promising underlying the possibility to detect the presence of a 
very small tumour at an early stage, an ideal setting for new drugs setting. Our results are 
quite interesting when compared with the ones obtained by Jundt et al, studying the same 
model macroscopically [26]. The authors obtained palpable lesions between one and two 
weeks, reaching an average tumour volume of 32.7mm3 at 16 days, while in our series a 
palpable mass was evident between two and three weeks. Differences in tumour cells phase of 
growth at the time of inoculation may have accounted for differences in time of formation of a 
palpable mass. Moreover, patterns of differential tumour growth may exist among different 
animals as reported by Sato et al in five SCID mice injected with Karpas 299 intraperitoneally 
[31]. 
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Tumour lesions presented a progressive increased metabolic activity, as expressed by mean 
TBR variations, especially in the first three weeks.  Afterwards, the TBR reaches a plateau 
which reflects the necrotic changes evident on the latest PET scans in the central areas of the 
tumour mass. The higher mean TBR value of the animals with first positive PET at 14 days 
compared with those with first positive PET at seven days, suggested the need to further 
assess one week PET-negative animals between 7 and 14 days, since it is likely that the 
tumour lesion may have been detected earlier.  
Pathologic examination showed a widespread tissue distribution including lungs, liver, 
kidneys, intestine, as well as adjacent fat and muscles. The widespread distribution of 
lymphoma cells in the alveolar spaces was the major reason why we chose the background 
ROI in the contra-lateral subcutaneous tissue instead of the lungs.  
In one case PET was negative at all time-points while autopsy revealed the presence of 
tumour cells at tracheal level without a macroscopically evident tumour mass. Although a 
localization of lymphoma cells at head and neck level has been reported after intravenous 
Karpas 299 cells administration [32], it is seems unlikely this is the case, since autopsy did 
not reveal any other site of tumour involvement that could be expected after cells intravenous 
injection. One possible explanation for this unusual localization could be advocated to a 
mistaken cells injection directly at mediastine level. 
 
CONCLUSIONS  
In this ALCL xenograft murine model small animal PET allowed the detection of tumour 
lesions before macroscopic evaluation at a very early stage. The selection of tumour bearing 
animals early in the course of the disease can be useful for new drugs testing studies and for 
monitoring tumour response to therapy. 
 
FUTURE DIRECTIONS.. 
Since small animal PET provided a good characterization of this tumour model, in the next 
future small animal PET will be used to assess tumour response to experimental anti-
proliferative drugs. 
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FIGURES SECTION 3 
Figure 3.1. Serial 18F-FDG small animal PET images of ALCL development after 
implantation of human Karpas 299 cells. Early PET scan was negative (2days) while PET 
performed at 7 days from tumour cells implantation showed the presence of a pathologic FDG 
uptake area at inoculation site. The metabolic activity of the mass progressively increased 
over time (14,21 days) while later scans showed cold areas in the context of the lesion 
reflecting the presence of necrotic areas (21,28 days). 
 
 
Figure 3.2. Tumour to background (TBR) variations over time in PET-positive tumour 
bearing animals showed a greater increase in the first three weeks. The TBR trend tended to a 
plateau at later time-points reflecting the presence of central necrotic areas. 
 
 
2d 7d 14d 21d 28d 
FDG-PET of a KARPAS 299 xenograft in a 6weeks old 
NOD/SCID mouse  
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Figure 3.3. Pathologic sections of a NOD/SCID mouse inoculated with the human ALCL 
Karpas 299 cell line. The tumour mass showed highly pleomorphic lymphoma cells with a 
high mitotic and apoptotic rate (A, 60x) and a big central necrotic area (B, 4x). The tumour 
was very aggressive, infiltrating adjacent muscles (C, 40x), the lungs (D, 4x; E, 20x) and the 
liver (F, 40x).  
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SECTION 4 
SMALL ANIMAL PET APPLICATIONS IN CARDIOLOGY (rat model of hear 
infarction) 
 
INTRODUCTION 
Heart disease is the most frequent cause of morbidity and mortality in the US and most 
western countries. Until recently, treatment of heart disease has been targeted on the anatomic 
and physiologic effects (coronary artery bypass surgery, percutaneous transluminal coronary 
angioplasty) for relieving obstructive coronary atherosclerosis. The recent advances in 
imaging technology enable innovative research and significant improvements in 
cardiovascular therapy. Non-invasive imaging of the integrative functions of molecules, 
genes, and cells in intact living subjects is now possible and provides a sophisticated 
evaluation of the disease process [1]. Multiple imaging technologies have been developed or 
adapted from human use for this purpose, including positron emission tomography (PET), 
single-photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), 
computed tomography (CT) targeted contrast ultrasound, bioluminescence, fluorescence, and 
near-infrared fluorescence (NIRF).  
Potential applications of molecular imaging in cardiovascular medicine include the analysis of 
vulnerable plaques, heart failure, neuro-hormonal dysfunction, myocardial metabolism, stem 
cell engraftment, protein–protein interactions, and angiogenesis. 
One of the main goals of research in cardiology is to identify an effective treatment strategy 
that could induce infarcted myocardial regeneration: cell transplantation to repair or 
regenerate injured myocardium (cellular cardiomyoplasty) has been proposed as a new 
approach for treatment [2,3]. Many pre-clinical studies tried to address this issue, much 
remains to be understood about this methodology, as well as its possible applications in the 
clinic. For example, controversies exist over the specific cells to be used, the dosages needed 
for tissue repair, how cells will affect the electrical activity of the myocardium, and even 
whether the cells can improve myocardial function after transplantation [4].  
Among all cell types used in the pre-clinical setting, only stem cells derived from the bone 
marrow, endothelial cells precursors and skeletal myoblasts have been used in clinical trials, 
mainly as a consequence of their availability, resistance to ischemia and ethical issues 
(compared to the use of human embryonic or fetal cells) [5,6,7]. 
Despite the initial enthusiasm of in-vitro and pre-clinical in-vivo studies, doubts have been 
raised about the potential of bone marrow stem cells to integrate into the myocardium and 
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differentiate into cardiac-like cells [8,9,10]. Autologous skeletal muscle precursors cells have 
been proposed as cell sources but there is no direct evidence of their ability to integrate in the 
myocardium from a morphological and functional point of view [8,11,12]. 
Factors that are indirectly correlated with cells engraftment include the cells paracrin activity 
with effects on the surrounding necrotic tissue and the cells ability to promote the release of 
angiogenetic factors that can induce extra-cellular matrix remodelling (lower collagen 
deposition with subsequent increase in myocardial compliance) [13,14]. 
Another crucial issue is the route of cells administration. Traditionally, the most popular 
method for cell transplantation into the heart is direct intramuscular injection, which allows 
the selective cell delivery into either normal or infarcted myocardium [15,16]. The main 
limitation of this is the mechanical injury and subsequent acute inflammation that results in 
poor survival of grafted cells and myocardial damage [11,12,17]. Furthermore, myocardial 
precursors cells infused by this method usually produce localized islet-like formations, 
isolated from the native myocardium [11]. Cells delivery via the intra-coronary route presents 
theoretical advantages over direct intramuscular injection allowing global cell dissemination 
within the myocardium [17,18]. This method is also likely to result in less myocardial and 
graft injury. Recent evidence demonstrated that myocardial precursors cells grafted by 
antegrade intra-coronary infusion successfully disseminated throughout cardiac layers, 
proliferated, differentiated, and integrated into host myocardium in rat [17,18]. Moreover, 
antegrade intra-coronary myocardial precursors cells transplantation resulted in cardiac 
function improvement in rats with doxorubicin-induced heart failure [19]. This route has 
recently been applied for infusion of bone marrow stem cells into infarcted human hearts [2]. 
However, some authors reported that antegrade intra-coronary infusion is not the best 
administration route to deliver cells to ischemic or infarcted areas and is associate with a risk 
of coronary embolism [17,18,19]. A novel approach consists in the retrograde intra-coronary 
delivery, that is an efficient way to administer cardioplegic solutions, peptides, and vectors for 
gene therapy into the myocardium of laboratory animal [20-23]. Emigration of inflammatory 
cells into the myocardial interstitium is known to take place at post-capillary venules rather 
than at arterioles or capillaries [24]. Retrograde intra-coronary infusion might offer a safer 
and more efficient cell dissemination within the myocardium even in ischemic or infracted 
areas where antegrade arterial delivery has been reported to have limited efficacy.  
Over the past decades, nuclear medicine has gained a relevant role for the assessment of 
cardiologic disorders in humans. In particular, PET has contributed significantly to advances 
in understanding heart physiology and pathophysiology (in-vivo quantitation of heart 
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perfusion, heart viability) and pre-clinical PET is nowadays an accurate tool for the 
assessment of heart function.  
Direct molecular imaging allows the evaluation of myocardial viability and heart perfusion 
using tracers such as 18F-FDG, 82-Rb, 13N-ammonia, 15O-water. Although these techniques 
found several applications in pre-clinical imaging, they are all widely used in the human 
patient. A different approach is reporter imaging that consists of in-vitro genetic labelling of 
target cells that are subsequently injected in the animal and detected by small animal PET 
(e.g. HSV1-FHBG). Reporter imaging finds application for the in-vivo study of stem cells, a 
potential therapeutic strategy for the regeneration of infarcted heart. 
Imaging of molecular markers (such as VEGF, integrins, annexins) that are over-expressed 
only in specific pathologic conditions. 
From a clinical point of view, the assessment of myocardial viability in patients with 
decreased left ventricular function is a very important issue since patients with evidence of 
viability that undergo revascularization have better survival compared to those who receive 
medical management [25-28] and a significant proportion of patients with depressed left 
ventricular function have evidence of viability and can have improvement in left ventricular 
function following revascularization [29,30].  
To assess myocardial availability, the most commonly used tracer is 18F-FDG in both clinical 
and pre-clinical setting [31]. Viable myocardial cells (although stunned or ibernated) present 
an increased 18F-FDG uptake, depending on glucose and insulin serum levels [32-34].  
Therefore 18F-FDG is the tracer of choice for the assessment of viable myocardium. 
However, a fundamental question is how to measure the infarcted area in the laboratory 
animal, in order to perform comparative measures over time. It is important to note that the 
aim of performing 18F-FDG PET is different in the human patient and in the laboratory 
animal. In the clinical setting, it is crucial to identify those patients who would benefit more 
from a re-vascularization: especially when associated to a perfusion study, 18F-FDG PET 
allows to predict post-revascularization improvement in left ventricular function in case of 
mismatch between blood flow (Rb-82; O-15 water; N-13 ammonia) and FDG metabolism. In 
the pre-clinical setting it is fundamental to measure the volume of viable myocardium in order 
to assess the effect of experimental therapies (such as regenerative therapies using stem cells). 
In the present study, the preliminary data of an on-going study to evaluate the volume of 
viable myocardium in infarcted rats are described in detail. The role of small animal PET to 
assess the effects of an experimental regenerative treatment (cellular 
cardiomyoplasty+infusion of relaxin) to induce myocardial regeneration is also described.  
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METHODS 
Animal model 
We surgically induced a left ventricular anterior infarction through occlusion of the LAD (left 
anterior descendent) coronary artery (general anaesthesia: 50mg/kg i.p. pentobarbital; tracheal 
cannula: 14 Gauge; volume controlled mechanical ventilation: FiO2 80-100%, FR 45/min, 
I:E=0.7, PEEP 0,5cmH2O; descendant anterior coronary artery ligation after the first diagonal 
branch in order to minimize the extension of the induced infarct and to obtain a chronic 
cardiac insufficiency with a cardiac output of 30-35%) in 16 non-diabetic Wistar rats (200-
300gr). All surgical procedures were performed at the Experimental Surgery Laboratory, 
University of Florence. During the surgical procedure, blood pressure was invasively 
monitored at femoral artery level. Immediately after surgery, animals were allowed to recover 
in a warm box with increased oxigen flow.  
Infarcted animals were then divided into 2 groups: Cases (8 animals) and Controls (8 
animals). 
Control animals were studied by 18F-FDG PET at 4 wks, 5 wks and 7 wks after surgery.  
Case rats were studied 4 wks after surgery and then treated by i.v. infusion of mouse 
myoblasts (C2C12 cell line) genetically engineered to produce relaxin (2x106cells/100gr of 
body weight, suspended in 1ml of saline, were infused in 1 minute at coronary vein level), 
associated with i.p. implantation of a osmotic micro pumping device constantly releasing 
relaxin (5 mg/kg b.wt./day). This group was studied by small animal PET 1 wk, 2 wks and 5 
wks after cell grafting.  
Oral ciclosporin (15mg/kg) was administered in all animals to obtain immunosoppression 
after myoblasts/placebo infusion. 
 
Cells cultures 
Cells were cultured and engineered at the Unit of Cardiac Surgery, University of Florence. 
Mouse myoblasts (C2C12 cell line) were cultured in DMEM with 10% fetal calf serum, 
gentamicin-streptomicn (100U/ml) and maintained at 37°C and 5% CO2. Cells were 
genetically engineered to produce relaxin using a lenti-viral vector (containing the human 
gene RLN2, encoding for relaxin, and a reporter gene called eGFP, encoding for a fluorescent 
protein) [35]. These cells, called C212/RLX, were administered by retrograde intra-coronary 
infusion in Group 2 rats and were able to produce relaxin at a concentration of 1.8ng/ml, 
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pharmacologically active and measurable by ELISA. Cells clones were analyzed by 
fluorescence microscopy and flow cytometry to assess the expression of eGFP. 
 
Imaging by 18F-FDG PET 
All animals were i.p. administered a 5% glucose solution before the PET scan in order to 
increase insulin blood levels. PET scans were carried out under sevofluorane (5%) anaesthesia 
(VetEquip Complete Anaethesia System, Pleasanton, CA) and oxigen supplementation 
(1L/min). 
Small animal 18F-FDG PET (GE eXplore Vista DR) was performed after 1 month, 2 months 
and 3 months from myocardial infarction under standard procedures (18F-FDG tail vein 
injected dose 45MBq, uptake time 30min, acquisition time 20min, reconstruction OSEM2D). 
Animals were allowed to wake up during uptake time in a warm recovery box.  
In order to evaluate the volume of viable myocardium, we semi-automatically draw a volume 
of interest (VOI) over the left viable ventricle and used the small animal PET workstation 
software to calculate a volume including all surrounding areas presenting the same metabolic 
activity. In this way we obtained a measure of the viable myocardium that is complimentary 
to the infarcted area. We used this method to calculate the volume of viable myocardium scan 
by scan. Statistical significance between experimental values was determined by t testing, and 
differences were considered significant at p<0,005. 
 
PRELIMIANRY RESULTS 
The mean volume measured in cases and controls is shown in Figure 4.1. Treated animals had 
a mean increase of viable myocardium of  7%, 35% and 26%  at 1, 2 and 5 wks after cell 
infusion, respectively (Figure 4.2). The control group showed a mean increase of  14% and  
10% at 5 and 7 wks after surgery, respectively. The difference in the mean viable myocardium 
between cases and controls was statistically significant at the third scan (p=0,003). Comparing 
the volume of viable myocardium rat by rat, case rats presented a significant increase in 
viable myocardium between the second and first scan (p=0,04) and between the third and first 
scan (p=0,03) while controls presented a significant difference only between the second and 
first scan (p=0,02).  
Pathological examination of the myocardium is on-going to investigate the effects of 
myoblasts cell therapy. 
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DISCUSSION OF PRELIMINARY RESULTS 
Nuclear medicine has a relevant role in the assessment of heart pathophyiology in humans. 
With the advent of small animal PET tomographs, it is now possible to perform PET in 
rodents with heart disease.  
In our preliminary experience we developed a protocol in order to standardize the measure of 
viable myocardium assessed by small animal PET. A rat model of surgically induced heart 
infarction was serially studied by small animal PET with FDG at baseline (after ligation of the 
LAD) and at serial time-points in both controls (placebo) and rats treated with infusion of 
myoblasts engineered to produce relaxin associated with the implantation of a micro-pumping 
device releasing relaxin.  
Our preliminary data showed that small animal PET with 18F-FDG is an accurate tool to 
study the volume of viable myocardium after infarction in laboratory animals and to assess 
the response to regenerative treatment.  
The mean volume of viable myocardium was significantly higher in animals treated with 
myoblasts infusion associated with relaxin administration compared with control animals 
treated with placebo. The slight increase in the control at the second PET scan can be 
explained with the physiologic animal increase in body weight. In fact a major limit in this  
protocol is that performing serial PET scans over time the physiologic increase of the heart (in 
both cases and controls) has to be taken into account (especially since the heart does note 
increase proportionally to body weight). Pathological examination of the myocardium will be 
carried out to investigate the effects of myoblasts cell therapy and observe if there are any 
correlation with the total weight of the heart at the time of PET scan. 
At present, it is quite easy to measure the infarcted area in the human patient, since 
appropriate software are already available. In the pre-clinical setting, the issue is still debated 
although some authors reported that the extent of the infarcted area induced in the mouse or in 
the rat measured with manual or semi-automated  tools on PET images is strictly correlated 
with the pathological data [36]. In our protocol we measured the viable myocardium drawing 
a small volume of interest in the viable myocardium and used the PET workstation software 
to include the surrounding areas with the same metabolic activity in the volume of interest. In 
this way we obtained a parameter that could be used in longitudinal studies with the aim to 
assess the response to treatment.  
Another issue is to standardize myocardial glucose uptake in the animals. To overcome this 
problem, we administered each animal an i.p. glucose load 30 minutes before the PET scan in 
order to induce a shift of myocardial metabolism towards glucose consumption (in response 
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to the increased insulin serum levels). In this way we obtained a high uptake in the heart that 
allowed an accurate and standardized measure of the viable myocardium.  
 
FUTURE DIRECTIONS.. 
As already said these are just preliminary results of a protocol that also includes in the next 
future the assessment of the effects of relaxin and cardiomyoplasty alone in two additional 
groups of animals that will be studied by small animal PET following he same procedure 
described above. In this way we will be able to derive conclusions on the role of relaxin and 
cardiomyoplasty, associated or alone, in the increase of viable myocardium. In fact, some 
authors have suggested that relaxin may have a role in promoting the regeneration of ischemic 
heart by inducing modifications in the extra-cellular matrix that would favour the homing and 
local proliferation of administered stem cells [37-39]. Moreover, relaxin could influence 
blood local flow promoting myoblasts survival and supporting their growth [3,40,41].  
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FIGURES SECTION 4 
 
Figure 4.1 
Mean volume of viable myocardium in infarcted rats: cases (treated with myoblasts 
engineered to produce relaxin and relaxin administration by an osmotic micro-pumping) vs 
control animals (placebo). Treated animals had a mean increase of viable myocardium of  7%, 
35% and 26%  at 1, 2 and 5 wks after cell infusion, respectively. The control group showed a 
mean increase of  14% and  10% at 5 and 7 wks after surgery, respectively.  
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Figure 4.2 18F-FDG small animal PET axial images of an infarcted rat heart before and after 
regenerative therapy. 
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CONLUSIONS 
Small animal PET is safe for the serial assessment of laboratory animals, provides relevant 
data on tumour metabolism, on drug efficacy in animal models of human cancer and can be 
used in cardiology for the assessment of viable myocardium after infarction and/or 
regenerative therapy.  
